RecruitingNCT06933758

Temple Health Chest Initiative (THCI 2.0)

Temple Health Chest Initiative (THCI 2.0) - Lung Cancer Screening Project With COPD Detection


Sponsor

Temple University

Enrollment

1,000 participants

Start Date

Feb 28, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Chronic obstructive pulmonary disease is highly prevalent globally, with considerable morbidity and mortality associated. In the US, it is the 4th leading cause of death, as well as contributing to significant costs on healthcare utilization including hospitalization. Population-based screening for COPD has not been recommended by the US Preventative Services Task Force (USPSTF). However, LDCT screening for lung cancer in patients aged 50- 80 with ≥ 20 pack year smoking has been shown to improve survival. COPD is highly prevalent within LCS programs, with estimated rates of obstructive lung function of up to 59% and evidence of emphysema on CT scan in around 70%.


Eligibility

Min Age: 50 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

The Temple Health Chest Initiative (THCI 2.0) is a program designed to improve care for patients with chest-related conditions — including lung disease, heart disease, and chest pain — through coordinated screening, early detection, and follow-up. This is a quality improvement and care program, not a drug trial. **You may be eligible if...** - You are a patient at Temple Health or an affiliated clinic - You have risk factors for lung, heart, or chest conditions (such as smoking history, high blood pressure, or family history) - You are an adult who can participate in screening and follow-up appointments **You may NOT be eligible if...** - You are already enrolled in a comprehensive chest health management program - You have conditions that make standard chest screening inappropriate - You are unable or unwilling to attend follow-up visits Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTDetermine COPD prevalence utilizing spirometry along with CT scans and symptom assessments in the THCI lung cancer screening populatio

Demonstrate utility of LDCT in COPD characterization Determine exacerbation risk and symptom burden in this patient population Determine the severity of COPD identified through this process Describe phenotypic characteristics including imaging analysis of THCI population Determine the suitability and acceptance of patients to participate in COPD clinical trials Determine the incidence of comorbid lung (ILA, bronchiectasis, pulmonary artery enlargement) and non-lung problems (cardiac and aortic calcifications, osteopenia/osteoporosis and for gut abnormalities) identified by LDCT in a patient population at risk for lung cancer and/or COPD Determine the correlation between clinical measurements and imaging biomarkers


Locations(1)

Temple University Of the Commonwealth System of Higher Education

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06933758


Related Trials